Program
JMKX000197
A development code.
Its studies are mostly in Pleural Effusion, Malignant, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jemincare | 22 open or running | phase 1since May 23, 2023 | May 23, 2023 | none ahead |
| Shanghai Jeyou Pharmaceutical | 11 open or running | phase 2since Jun 10, 2026 | Jun 10, 2026 | Jan 12, 2028phase 2 · NCT07649369 |
Also a collaborator on its studies: zhejiang-hangyu-pharmaceutical-co-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 23, 2023First study: phase 1 study in Pleural Effusion, MalignantNew to JemincareJemincare · NCT05923515 · 78 planned · China
- Dec 13, 2024Phase 1 study in Pleural Effusion, MalignantJemincare · NCT06740019 · 30 planned · China
- Jun 10, 2026Shanghai Jeyou Pharmaceutical's first study: phase 2 study in Pleural Effusion, MalignantNew to Shanghai Jeyou PharmaceuticalShanghai Jeyou Pharmaceutical · NCT07649369 · 120 planned · China
Ahead
- Jan 12, 2028Primary completion: phase 2 study in Pleural Effusion, MalignantShanghai Jeyou Pharmaceutical · NCT07649369
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07649369Pleural Effusion, Malignant · China | 2 | Not yet recruiting | Shanghai Jeyou Pharmaceutical | Jan 12, 2028 | 120 |
| NCT06740019Pleural Effusion, Malignant · China | 1 | Recruiting | Jemincare | Dec 31, 2025 | 30 |
| NCT05923515Pleural Effusion, Malignant · China | 1 | Recruiting | Jemincare | Apr 30, 2025 | 78 |
How it is read
Names in the registry
- “JMKX000197”, 3 entries
Codes read as this program: JMKX000197.
Conditions, from the studies’ own filings
- Pleural Effusion, Malignant, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.